Brought to you by 
BMS and Pharmasset bring together HCV candidates
04 Mar 2016
Executive Summary
Bristol-Myers Squibb Co. and Pharmasset Inc. (infectious disease therapeutics) have teamed up to create a combination treatment of their oral chronic hepatitis C drug candidates--BMS’s BMS790052 and Pharmasset’s PSI7977.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS and Pharmasset bring together HCV candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice